Category: Other

post image

Investigational anti-inflammatory drug meets primary endpoint in global Phase III CANTOS outcome study

In line with the ground-breaking concept of REPROGRAM not only the cholesterol lowering PCSK9 inhibitors seem to be effective. But now, a purely anti-inflammatory cardiovascular trial with the IL-1ß blocker was positive. Thus, both hypotheses seem to be correct, the cholesterol and the inflammation hypotheses of treating cardiovascular disease.   The global Phase III CANTOS

Read More →

This project has received funding from the European Union's Horizon 2020 research and innovation programme under grant agreement N°667837.